Publications & References

1. Carpentier AF, Chen L, Maltonti F, Delattre JY. (1999). Oligodesoxynucleotides containing CpG motifs can cure neuroblastoma in mice. Cancer Research, 59, 5429-5432.

2. Use of stabilised oligonucleotides for preparing a medicine with antitumor activity. Propriétaires AP/HP et INSERM. Inventor: AF Carpentier. 19/3/99. Patents US No. 7,108,844; US n°7,700,569; Fr 99 03433, EP 1162982 B1

3. Carpentier AF, Xie J, Mokthari K, Delattre JY. (2000). Successful treatment of intracranial gliomas in rats with oligodeosynucleotides containing CpG motifs. Clinical Cancer Research, 6: 2469-73.

4. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. (2001). Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res; 7: 3540-3.

5. Meng Y, Carpentier AF; Chen L; Boisserie G; Simon JM; Mazeron JJ; Delattre JY. (2005). Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer;116: 992-7.

6. Carpentier A, Zohar S, Capelle L, Behin A, Tibi A, Laigle-Donadey F, Puybasset L, Sanson M, Van Effenterre R; Delattre JY, Carpentier AF. (2006). Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology, 8: 60-6.

7. Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, Carpentier AF. Expression of TLR9 within human glioblastoma. J Neurooncol. 2008; 88:19-25.

8. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, Zitvogel L, Mir LM, Robert C. Tumor destruction using elec

9. trochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother. 2008; 57: 1291-300.

10. Chennaoui M, Drogou C, Carpentier AF, Guezennec CY, Gomez-Merino D. Cytokine content in lymphoid and white adipose tissues after repeated CpG oligodeoxynucleotide administration in trained rats. Vaccine. 2010; 28: 1814-8.

11. Carpentier A , Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M; Meng Y, Richard M, Parizot C, Laigle-Donadey F; Gorochov G, Psimaras D, Sanson M, Tibi A, Chinot O, Carpentier AF. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma – a phase 2 study. (2010) Neuro-oncology, 2010;12:401-8.

12. Maubant S, Banissi C, Beck S, Chauvat A, Carpentier AF. Adjuvant Properties of Cytosine-Phosphate-Guanosine Oligodeoxynucleotide in Combination with Various Polycations in an Ovalbumin-Vaccine Model. Nucleic Acid Ther. 2011;21(4):231-40.

13. Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol. 2012;746:95-108. Review.

14. Ursu R, Taillibert S, Banissi C, Vicaut E, Bailon O, Le Rhun E, Guillamo JS, Psimaras D, Tibi A, Sacko A, Marantidou A, Belin C, Carpentier AF. Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial. Cancer Sci. 2015;106:1212-8.

15. Macedo R, Rochefort J, Guillot-Delost M, Tanaka K, Le Moignic A, Noizat C, Baillou C, Mateo V, Carpentier AF, Tartour E, Bertolus C, Bellier B, Lescaille G, Lemoine FM. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles. Oncoimmunology. 2016 Jul 6;5(7):e1164363

16. Schaedler E, Remy-Ziller C, Hortelano J, Kehrer N, Claudepierre MC, Gatard T, Jakobs C, Préville X, Carpentier AF, Rittner K. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors. Vaccine. 2017;35:577-585.

17. Ursu R, Carpentier A, Metellus P, Lubrano V, Laigle-Donadey F, Capelle L, Guyotat J, Langlois O, Bauchet L, Desseaux K, Tibi A, Chinot O, Lambert J, Carpentier AF. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. Eur J Cancer. 2017;73:30-37.

Contact

Oligovax SAS
102 avenue des Champs Elysées
75008 Paris
France
oligovax@net-c.com

© Copyright Oligovax 2018 - All Rights Reserved
Mentions légales : Site et contenus propriétés d'Oligovax
Création et intégration : Justine Gélis / Justincreations.fr - Hébergeur OVH